References
- Shippee BM, Bates JS, Richards KL. The role of screening and monitoring for bleomycin pulmonary toxicity. J Oncol Pharm Pract. 2016;22:308–312.
- O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–96.
- Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood. 2015;125:1693–1702.
- Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease – a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007;92:e120–e121.
- von Rohr L, Klaeser B, Joerger M, et al. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie. 2007;30:320–323.
- Kazama T, Faria S, Uchida Y, et al. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med. 2008;22:111–114.
- Kirsch J, Arrossi AV, Yoon JK, et al. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis. J Thorac Imaging. 2006;21:228–230.
- Connerotte T, Lonneux M, de Meeûs Y, et al. Use of 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography in the early diagnosis of asymptomatic bleomycin-induced pneumonitis. Ann Hematol. 2008;87:943–945.
- Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol. 1990;8:765–767.
- Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol. 1996;14:1297–1305.
- Jensen JL, Goel R, Venner PM. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer. 1990;65:1291–1297.
- Chen DL, Schuster DP. Imaging pulmonary inflammation with positron emission tomography: a biomarker for drug development. Mol Pharm. 2006;3:488–495.
- Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058.
- Batra S, Vaid AK, Bhargava R, et al. Lungs on fire. BMJ Case Rep. 2013;2013. doi:10.1136/bcr-2013-010388.
- Santrach PJ, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer. 1989;64:806–811.
- Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
- Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–695.
- Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161:76–86.
- Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–624.
- McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol. 1990;8:779–783.
- Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372:1598–1607.
- Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Blood. 2014;124:3356–3364.
- Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23:7614–7620.